Path's proprietary phenotypic screening platform is exposing new therapeutics and novel druggable targets for diseases of the central nervous system, including rare forms of epilepsy, autism, and aging.
Location: Canada, Alberta, Calgary
Investors 2
| Date | Name | Website |
| - | Innovate C... | innovateca... |
| 01.06.2021 | Creative D... | creativede... |